J. M. Sullivan

发表

Development of lead hammerhead ribozyme candidates against human rod opsin mRNA for retinal degeneration therapy.

M. Zuker, H. E. Abdelmaksoud, E. Yau, 2009, Experimental eye research.

Optimizing case-control classification for age-related macular degeneration in the VA electronic health record using a multi-algorithm data cube approach

Dana C. Crawford, Sudha K. Iyengar, Robert P. Igo, 2018 .

Variables and Strategies in Development of Therapeutic Post-Transcriptional Gene Silencing Agents

H. E. Abdelmaksoud, E. Yau, J. M. Sullivan, 2011, Journal of ophthalmology.

Log-order improved in trans hammerhead ribozyme turnover rates: reevaluating therapeutic space for small catalytic RNAs

J. M. Sullivan, J. Myers, J. Sullivan, 2022, bioRxiv.

A high-throughput biophotonics instrument to screen for novel ocular photosensitizing therapeutic agents.

M. C. Butler, J. M. Sullivan, P. Itotia, 2010, Investigative ophthalmology & visual science.

Genetically-guided algorithm development and sample size optimization for age-related macular degeneration cases and controls in electronic health records from the VA Million Veteran Program.

Matthew D. Anger, D. Crawford, J. M. Sullivan, 2019, AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science.

Glaucoma genetic risk scores in the Million Veteran Program.

D. Crawford, J. M. Sullivan, S. Iyengar, 2022, Ophthalmology.

Rapid, cell-based toxicity screen of potentially therapeutic post-transcriptional gene silencing agents.

J. M. Sullivan, Tiffany A. Kolniak, J. Sullivan, 2011, Experimental eye research.

Distinctive cross-ancestry genetic architecture for age-related macular degeneration

Matthew D. Anger, B. Yaspan, D. Crawford, 2022, medRxiv.

Electrical approach to study rhodopsin activation in single cells with early receptor current assay.

J. M. Sullivan, L. Brueggemann, P. Shukla, 2000, Methods in enzymology.

Ultrahigh Resolution Mouse Optical Coherence Tomography to Aid Intraocular Injection in Retinal Gene Therapy Research.

M. C. Butler, J. M. Sullivan, J. Sullivan, 2018, Journal of visualized experiments : JoVE.

Effects of Pathogenic Variations in the Human Rhodopsin Gene (hRHO) on the Predicted Accessibility for a Lead Candidate Ribozyme

J. M. Sullivan, Alexandria J. Trujillo, Beau R. Froebel, 2017, Investigative ophthalmology & visual science.

Relieving bottlenecks in RNA drug discovery for retinal diseases.

M. C. Butler, E. Yau, J. M. Sullivan, 2012, Advances in experimental medicine and biology.

Optimization of Ribozyme Agents for Human Rod Opsin Therapeutics

E. Yau, J. M. Sullivan, Tiffany A. Kolniak, 2008 .

High Throughput Cellular Screening for Ribozyme Development Against Arbitrary mRNA Targets

E. Yau, J. M. Sullivan, 2007 .

Novel and Enhanced Approaches to Determine Local mRNA Accessibility

J. M. Sullivan, R. Taggart, 2007 .

Identification of Lead Candidate Ribozymes for Human Rod Opsin Therapeutics

E. Yau, J. M. Sullivan, Tiffany A. Kolniak, 2007 .

Properties of Rhodopsin Regeneration in HEK293S Cells

J. M. Sullivan, P. Itotia, N. Bath, 2007 .

Cell–Based High–Throughput Screening of Rationally Designed Ribozymes

E. Yau, J. M. Sullivan, 2006 .

Fundus autofluorescence and photoreceptor cell rosettes in mouse models.

J. M. Sullivan, J. Sparrow, K. Ueda, 2014, Investigative ophthalmology & visual science.

HEK293S Cells Have Functional Retinoid Processing Machinery

Jack M. Sullivan, J. M. Sullivan, Lioubov I. Brueggemann, 2002, The Journal of general physiology.

All-trans-retinal forms a visible-absorbing pigment with human rod opsin.

J. M. Sullivan, L. Brueggemann, 2001, Biochemistry.

Pediatric Hereditary Macular Degenerations

R. Spencer, D. Birch, J. M. Sullivan, 2011 .

Low-cost monochromatic microsecond flash microbeam apparatus for single-cell photolysis of rhodopsin or other photolabile pigments

Jack M. Sullivan, J. M. Sullivan, J. Sullivan, 1998 .

Normal and Mutant Rhodopsin Activation Measured with the Early Receptor Current in a Unicellular Expression System

J. M. Sullivan, P. Shukla, J. Sullivan, 1999, The Journal of general physiology.

Time-resolved rhodopsin activation currents in a unicellular expression system.

J. M. Sullivan, J M Sullivan, P Shukla, 1999, Biophysical journal.

Hammerhead ribozymes designed to cleave all human rod opsin mRNAs which cause autosomal dominant retinitis pigmentosa.

J. M. Sullivan, J. Misasi, K. Pietras, 2002, Molecular vision.

A cellular high-throughput screening approach for therapeutic trans-cleaving ribozymes and RNAi against arbitrary mRNA disease targets.

M. C. Butler, E. Yau, J. M. Sullivan, 2016, Experimental eye research.

Bottlenecks in development of retinal therapeutic post-transcriptional gene silencing agents

M. C. Butler, E. Yau, J. M. Sullivan, 2008, Vision Research.

Systematic Screening, Rational Development, and Initial Optimization of Efficacious RNA Silencing Agents for Human Rod Opsin Therapeutics

M. C. Butler, E. Yau, J. M. Sullivan, 2019, Translational vision science & technology.